- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05564390
MyeloMATCH MSRP: uno studio di screening per assegnare le persone con cancro mieloide a uno studio terapeutico
Master Screening and Reassessment Protocol (MSRP) per gli studi clinici NCI MyeloMATCH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
- Droga: Cytarabine
- Droga: Gemtuzumab Ozogamicin
- Procedura: Bone Marrow Biopsy
- Biologico: Epoetin Alfa
- Procedura: Computed Tomography
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Procedura: Biopsy Procedure
- Procedura: Positron Emission Tomography
- Procedura: Bone Marrow Aspiration
- Droga: Daunorubicin
- Droga: Daunorubicin Hydrochloride
- Droga: Busulfan
- Droga: Venetoclax
- Droga: Fludarabine
- Droga: Decitabine and Cedazuridine
- Droga: Placebo Administration
- Droga: Azacitidine
- Droga: Liposome-encapsulated Daunorubicin-Cytarabine
- Procedura: Biospecimen Collection
- Droga: Enasidenib
- Biologico: Luspatercept
- Biologico: Emavusertib
- Droga: Gilteritinib
- Droga: Olutasidenib
- Altro: Best Practice
- Droga: Quizartinib
- Procedura: Allogeneic Hematopoietic Stem Cell Transplantation
- Procedura: Chest Radiography
- Droga: Melphalan
- Radiazione: Total-Body Irradiation
- Procedura: Mutation Carrier Screening
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.
II. Tier Advancement Pathway (TAP): To enable participants who are not matched to an investigational myeloMATCH treatment substudy to receive standard of care (SOC) while remaining on the MSRP to maintain access to later tiers of treatment substudies.
SECONDARY OBJECTIVES:
I. Screening and Reassessment (MSRP):
Ia. To describe the time to generation of all data required for treatment substudy (or TAP) assignment, time to treatment substudy (or TAP) assignment, percent assigned to a myeloMATCH treatment substudy, and the percent of screened participants who register to a myeloMATCH investigational treatment substudy or are assigned to TAP:
Iai. Separately within each tier of myeloMATCH treatment substudy and analogous TAP assignment; Ibi. Separately within each clinical basket of myeloMATCH treatment substudies; Ici. Over time, across and within the categories above.
II. Tier Advancement Pathway (TAP):
IIa. To evaluate participants for assignment to higher tier treatment substudies within myeloMATCH; IIb. To describe, within tier- and basket- levels of TAP, measurable residual disease (MRD) rates and clonal evolution; IIc. To describe, within tier- and basket- levels of TAP, remission status and overall survival of participants who receive standard of care therapy; IId. To obtain MDNet specimens for translational medicine and biobanking.
OUTLINE:
REGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.
TAP: Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.
TREATMENT: Patients are assigned to a specific treatment substudy.
MM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid leukemia (AML) are randomized to 1 of 3 arms.
ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once daily (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening.
ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
MM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 5 arms.
ARM I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM III: Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
MM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have completed a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with partial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (> 0.1%) are randomized to 1 of 4 arms.
ARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
MM1OA-EA02: Patients are randomized to 1 of 3 regimens.
REGIMEN 1:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 2:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 3:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
MM1MDS-A01: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 1. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
REGIMEN 2: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
MM1OA-S03: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
MM1YA-A04: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.
REGIMEN 2: Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.
MM3TCT-A03: Patients with matched donors are randomized to conditioning 1A or 1B. Patients with haploidentical or mismatched unrelated donors are randomized to conditioning 2A or 2B.
CONDITIONING 1A: Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or twice daily (BID) on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 1B: Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2A: Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2B: Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: All patients without evidence of relapse at day +100 are re-randomized to maintenance I or II.
MAINTENANCE I: Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo positron emission tomography (PET) scan and/or computed tomography (CT) scan throughout the study.
MM1OA-MDS-A05: Patients are assigned to 1 of 3 cohorts.
COHORT A: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT B: Patients are randomized to 1 of 2 arms.
ARM 3: Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 4: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT C: Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
MM1MDS-CTG02: This is a dose-escalation study of luspatercept in combination, dependent upon arms assignments, with fixed dose epoetin alfa or emavusertib. Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 2: Patients receive luspatercept SC on day 1 and epoetin alfa SC once weekly (QW) for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 3: Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
MM1YA-EA05: Patients are randomized to 1 of 2 arms.
ARM A:
INDUCTION: Patients receive cytarabine IV, over 24 hours, on days 1-7, daunorubicin IV on days 1-3, and quizartinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspiration/biopsy. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts may repeat induction as described starting on day 28-45. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation, following count recovery, by 30 days post-confirmation of CR/CRi. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts repeat the bone marrow aspiration/biopsy 1 week later and then either repeat induction or proceed to consolidation, based on results. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation.
CONSOLIDATION: Patients receive cytarabine IV, over 1-3 hours, every 12 hours on days 1, 3 and 5 and quizartinib PO QD on days 6-19 in the absence of disease progression or unacceptable toxicity.
ARM B:
CYCLE 1: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients undergo bone marrow aspiration/biopsy on day 14 of cycle 1. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue treatment as described through day 28 of cycle 1 and then proceed to cycle 2 without interruption or delay, as long as repeat bone marrow aspiration/biopsy on day 28 of cycle 1 is consistent with persistent blasts > 5%. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs.
CYCLE 2: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients who do not achieve response after completion of cycle 1 undergo bone marrow aspiration/biopsy on day 14 of cycle 2. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue venetoclax and quizartinib as described through day 28 of cycle 2. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28). Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat aspiration/biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28).
Upon completion of two cycles of therapy on either Arm A or Arm B, patients who are eligible can proceed to allogeneic stem cell transplant; while awaiting allogeneic stem cell transplant, patients should continue standard of care therapy.
Patients undergo echocardiography or MUGA scan during screening and undergo bone marrow aspiration and biopsy as well as blood sample collection throughout the study.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Reclutamento
- Arthur J E Child Comprehensive Cancer Centre
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-823-5923
- Email: ctsucontact@westat.com
-
Investigatore principale:
- Mary L. Savoie
-
Edmonton, Alberta, Canada, T6G 2B7
- Reclutamento
- University of Alberta Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 780-407-8798
- Email: pedsoncologyresearch@ahs.ca
-
Investigatore principale:
- Joseph M. Brandwein
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Reclutamento
- CancerCare Manitoba
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-561-1026
- Email: ctu_web@cancercare.mb.ca
-
Investigatore principale:
- Brett L. Houston
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Reclutamento
- QEII Health Sciences Centre/Nova Scotia Health Authority
-
Contatto:
- Site Public Contact
- Numero di telefono: 902-473-6000
-
Investigatore principale:
- Mahmoud Elsawy
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Reclutamento
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 905-387-9495
-
Investigatore principale:
- Alejandro Garcia-Horton
-
Ottawa, Ontario, Canada, K1H 8L6
- Reclutamento
- Ottawa Hospital and Cancer Center-General Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 613-761-4395
-
Investigatore principale:
- Mitchell Sabloff
-
Toronto, Ontario, Canada, M5G 2M9
- Sospeso
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Reclutamento
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
Contatto:
- Site Public Contact
- Numero di telefono: 416-480-5000
-
Investigatore principale:
- Rena J. Buckstein
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Reclutamento
- CSSS Champlain-Charles Le Moyne
-
Contatto:
- Site Public Contact
- Numero di telefono: 450-466-5065
-
Investigatore principale:
- Sami Morin-Ben Abdallah
-
Montreal, Quebec, Canada, H3T 1E2
- Reclutamento
- Jewish General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 8248 514-340-8222
-
Investigatore principale:
- Sarit E. Assouline
-
Montreal, Quebec, Canada, H1T 2M4
- Reclutamento
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Investigatore principale:
- Julie Bergeron
-
Contatto:
- Site Public Contact
- Numero di telefono: 3329 514-252-3400
-
-
-
-
-
San Juan, Porto Rico, 00927
- Reclutamento
- Centro Comprensivo de Cancer de UPR
-
Investigatore principale:
- Luis J. Santos Reyes
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-823-5923
- Email: ctsucontact@westat.com
-
San Juan, Porto Rico, 00936
- Reclutamento
- San Juan City Hospital
-
Investigatore principale:
- Luis J. Santos Reyes
-
Contatto:
- Site Public Contact
- Numero di telefono: 787-763-1296
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- University of Alabama at Birmingham Cancer Center
-
Investigatore principale:
- Razan Mohty
-
Contatto:
- Site Public Contact
- Email: gingerreeves@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85054
- Reclutamento
- Mayo Clinic Hospital in Arizona
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- James M. Foran
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- Banner University Medical Center - Tucson
-
Investigatore principale:
- Sharad Khurana
-
Contatto:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- University of Arizona Cancer Center-North Campus
-
Investigatore principale:
- Sharad Khurana
-
Contatto:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- University of Arkansas for Medical Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-686-8274
-
Investigatore principale:
- Ankur Varma
-
-
California
-
Berkeley, California, Stati Uniti, 94704
- Attivo, non reclutante
- Alta Bates Summit Medical Center-Herrick Campus
-
Dublin, California, Stati Uniti, 94568
- Reclutamento
- Kaiser Permanente Dublin
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
-
Investigatore principale:
- Faisal N. Cheema
-
Fremont, California, Stati Uniti, 94538
- Reclutamento
- Kaiser Permanente-Fremont
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Fresno, California, Stati Uniti, 93720
- Sospeso
- Kaiser Permanente-Fresno
-
Fresno, California, Stati Uniti, 93720
- Reclutamento
- Kaiser Permanente Fresno Orchard Plaza
-
Contatto:
- Site Public Contact
- Numero di telefono: 833-574-2273
-
Investigatore principale:
- Faisal N. Cheema
-
Irvine, California, Stati Uniti, 92612
- Reclutamento
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Investigatore principale:
- Deepa Jeyakumar
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-8839
- Email: ucstudy@uci.edu
-
Long Beach, California, Stati Uniti, 90822
- Attivo, non reclutante
- Tibor Rubin VA Medical Center
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars-Sinai Medical Center
-
Investigatore principale:
- Noah M. Merin
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-423-2133
- Email: Cancer.trial.info@cshs.org
-
Modesto, California, Stati Uniti, 95356
- Sospeso
- Kaiser Permanente-Modesto
-
Modesto, California, Stati Uniti, 95356
- Reclutamento
- Kaiser Permanente- Modesto MOB II
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
-
Investigatore principale:
- Faisal N. Cheema
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente-Oakland
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Investigatore principale:
- Deepa Jeyakumar
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-8839
- Email: ucstudy@uci.edu
-
Roseville, California, Stati Uniti, 95661
- Reclutamento
- Kaiser Permanente-Roseville
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California Davis Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 916-734-3089
-
Investigatore principale:
- Brian A. Jonas
-
Sacramento, California, Stati Uniti, 95814
- Reclutamento
- Kaiser Permanente Downtown Commons
-
Investigatore principale:
- Faisal N. Cheema
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: kpoct@kp.org
-
Sacramento, California, Stati Uniti, 95823
- Reclutamento
- Kaiser Permanente-South Sacramento
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
San Francisco, California, Stati Uniti, 94115
- Reclutamento
- Kaiser Permanente-San Francisco
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
San Francisco, California, Stati Uniti, 94143
- Reclutamento
- UCSF Medical Center-Parnassus
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-3222
-
Investigatore principale:
- Timothy Ferng
-
San Jose, California, Stati Uniti, 95119
- Reclutamento
- Kaiser Permanente-Santa Teresa-San Jose
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
San Leandro, California, Stati Uniti, 94577
- Reclutamento
- Kaiser Permanente San Leandro
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
San Rafael, California, Stati Uniti, 94903
- Reclutamento
- Kaiser San Rafael-Gallinas
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Santa Clara, California, Stati Uniti, 95051
- Reclutamento
- Kaiser Permanente Medical Center - Santa Clara
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Santa Rosa, California, Stati Uniti, 95403
- Reclutamento
- Kaiser Permanente-Santa Rosa
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
South San Francisco, California, Stati Uniti, 94080
- Reclutamento
- Kaiser Permanente-South San Francisco
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Vallejo, California, Stati Uniti, 94589
- Reclutamento
- Kaiser Permanente-Vallejo
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
Walnut Creek, California, Stati Uniti, 94596
- Reclutamento
- Kaiser Permanente-Walnut Creek
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Investigatore principale:
- Jan P. Bewersdorf
-
West Haven, Connecticut, Stati Uniti, 06516
- Reclutamento
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 2832 203-937-3421
-
Investigatore principale:
- Alexander Pine
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- UF Health Cancer Institute - Gainesville
-
Contatto:
- Site Public Contact
- Numero di telefono: 352-273-8010
-
Investigatore principale:
- Dina G. Khalaf
-
Jacksonville, Florida, Stati Uniti, 32224-9980
- Reclutamento
- Mayo Clinic in Florida
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- James M. Foran
-
Miami, Florida, Stati Uniti, 33176
- Reclutamento
- Miami Cancer Institute
-
Investigatore principale:
- Firas El Chaer
-
Contatto:
- Site Public Contact
- Numero di telefono: 786-596-2000
-
Pembroke Pines, Florida, Stati Uniti, 33028
- Reclutamento
- Memorial Hospital West
-
Contatto:
- Site Public Contact
- Numero di telefono: 954-265-4325
-
Investigatore principale:
- Yehuda E. Deutsch
-
Ruskin, Florida, Stati Uniti, 33570
- Reclutamento
- Moffitt Cancer Center at SouthShore
-
Investigatore principale:
- Rory M. Shallis
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Tampa, Florida, Stati Uniti, 33607
- Reclutamento
- Moffitt Cancer Center-International Plaza
-
Investigatore principale:
- Rory M. Shallis
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Moffitt Cancer Center - McKinley Campus
-
Investigatore principale:
- Rory M. Shallis
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Moffitt Cancer Center
-
Investigatore principale:
- Rory M. Shallis
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Wesley Chapel, Florida, Stati Uniti, 33544
- Reclutamento
- Moffitt Cancer Center at Wesley Chapel
-
Investigatore principale:
- Rory M. Shallis
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
-
Georgia
-
Albany, Georgia, Stati Uniti, 31701
- Reclutamento
- Phoebe Putney Memorial Hospital
-
Investigatore principale:
- Vamsi Kota
-
Contatto:
- Site Public Contact
- Numero di telefono: 229-312-0405
- Email: ga_cares@augusta.edu
-
Augusta, Georgia, Stati Uniti, 30912
- Reclutamento
- Augusta University Medical Center
-
Investigatore principale:
- Vamsi Kota
-
Contatto:
- Site Public Contact
- Numero di telefono: 706-721-2388
- Email: ga_cares@augusta.edu
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Reclutamento
- Kapiolani Medical Center for Women and Children
-
Investigatore principale:
- Craig S. Boddy
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-983-6090
-
Honolulu, Hawaii, Stati Uniti, 96813
- Reclutamento
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Investigatore principale:
- Craig S. Boddy
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-524-6115
- Email: i.webster@hawaiicancercare.com
-
Honolulu, Hawaii, Stati Uniti, 96813
- Reclutamento
- Straub Clinic and Hospital
-
Investigatore principale:
- Craig S. Boddy
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-522-4333
-
Honolulu, Hawaii, Stati Uniti, 96819
- Reclutamento
- Kaiser Permanente Moanalua Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-432-5195
- Email: shelley.a.clark@kp.org
-
Investigatore principale:
- Faisal N. Cheema
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Reclutamento
- Hawaii Cancer Care - Westridge
-
Investigatore principale:
- Craig S. Boddy
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-539-2273
- Email: info@hawaiicancercare.com
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Reclutamento
- Pali Momi Medical Center
-
Investigatore principale:
- Craig S. Boddy
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-486-6000
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Reclutamento
- Saint Luke's Cancer Institute - Boise
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Investigatore principale:
- Charles W. Drescher
-
Boise, Idaho, Stati Uniti, 83706
- Reclutamento
- Saint Alphonsus Cancer Care Center-Boise
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Caldwell, Idaho, Stati Uniti, 83605
- Reclutamento
- Saint Alphonsus Cancer Care Center-Caldwell
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Reclutamento
- Kootenai Health - Coeur d'Alene
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Fruitland, Idaho, Stati Uniti, 83619
- Reclutamento
- Saint Luke's Cancer Institute - Fruitland
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Investigatore principale:
- Charles W. Drescher
-
Meridian, Idaho, Stati Uniti, 83642
- Reclutamento
- Saint Luke's Cancer Institute - Meridian
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Investigatore principale:
- Charles W. Drescher
-
Nampa, Idaho, Stati Uniti, 83687
- Reclutamento
- Saint Luke's Cancer Institute - Nampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Investigatore principale:
- Charles W. Drescher
-
Nampa, Idaho, Stati Uniti, 83687
- Reclutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Post Falls, Idaho, Stati Uniti, 83854
- Reclutamento
- Kootenai Clinic Cancer Services - Post Falls
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Stati Uniti, 83864
- Reclutamento
- Kootenai Clinic Cancer Services - Sandpoint
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60506
- Reclutamento
- Advocate Outpatient Center - Aurora
-
Investigatore principale:
- Thomas J. Saphner
-
Contatto:
- Site Public Contact
- Email: ncorp@aah.org
-
Barrington, Illinois, Stati Uniti, 60010
- Reclutamento
- Advocate Good Shepherd Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-842-4847
-
Investigatore principale:
- Thomas J. Saphner
-
Bloomington, Illinois, Stati Uniti, 61704
- Reclutamento
- Illinois CancerCare-Bloomington
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Bloomington, Illinois, Stati Uniti, 61701
- Reclutamento
- OSF Saint Joseph Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Canton, Illinois, Stati Uniti, 61520
- Reclutamento
- Illinois CancerCare-Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Carthage, Illinois, Stati Uniti, 62321
- Reclutamento
- Illinois CancerCare-Carthage
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Investigatore principale:
- Olatoyosi M. Odenike
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern University
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-695-1301
- Email: cancer@northwestern.edu
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- University of Illinois
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-355-3046
-
Investigatore principale:
- Noah Birch
-
Chicago, Illinois, Stati Uniti, 60657
- Reclutamento
- Advocate Illinois Masonic Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-296-5360
-
Investigatore principale:
- Thomas J. Saphner
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- Rush MD Anderson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-226-2371
- Email: Cancer_Studies@rush.edu
-
Investigatore principale:
- Melissa L. Larson
-
Crystal Lake, Illinois, Stati Uniti, 60014
- Reclutamento
- AMG Crystal Lake - Oncology
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-929-6129
- Email: advocateresearch@advocate.com
-
Investigatore principale:
- Thomas J. Saphner
-
Danville, Illinois, Stati Uniti, 61832
- Reclutamento
- Carle at The Riverfront
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@Carle.com
-
DeKalb, Illinois, Stati Uniti, 60115
- Reclutamento
- Northwestern Medicine Cancer Center Kishwaukee
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Decatur, Illinois, Stati Uniti, 62526
- Reclutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Stati Uniti, 62526
- Reclutamento
- Decatur Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Stati Uniti, 61021
- Reclutamento
- Illinois CancerCare-Dixon
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 815-285-7800
-
Downers Grove, Illinois, Stati Uniti, 60515
- Reclutamento
- Advocate Good Samaritan Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-275-1270
- Email: Barbara.barhamand@advocatehealth.com
-
Investigatore principale:
- Thomas J. Saphner
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Carle Physician Group-Effingham
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Crossroads Cancer Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Stati Uniti, 60123
- Reclutamento
- Advocate Sherman Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-429-2907
-
Investigatore principale:
- Thomas J. Saphner
-
Eureka, Illinois, Stati Uniti, 61530
- Reclutamento
- Illinois CancerCare-Eureka
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Evanston, Illinois, Stati Uniti, 60201
- Reclutamento
- NorthShore University HealthSystem-Evanston Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Investigatore principale:
- Robert M. Eisner
-
Galesburg, Illinois, Stati Uniti, 61401
- Reclutamento
- Illinois CancerCare-Galesburg
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Geneva, Illinois, Stati Uniti, 60134
- Reclutamento
- Northwestern Medicine Cancer Center Delnor
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Glenview, Illinois, Stati Uniti, 60026
- Reclutamento
- NorthShore University HealthSystem-Glenbrook Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Investigatore principale:
- Robert M. Eisner
-
Glenview, Illinois, Stati Uniti, 60026
- Reclutamento
- Northwestern Medicine Glenview Outpatient Center
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-695-1102
-
Grayslake, Illinois, Stati Uniti, 60030
- Reclutamento
- Northwestern Medicine Grayslake Outpatient Center
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-695-1102
-
Harvey, Illinois, Stati Uniti, 60426
- Reclutamento
- Ingalls Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-915-4673
- Email: clinicaltrials@ingalls.org
-
Investigatore principale:
- Kimberly R. Kruczek
-
Hazel Crest, Illinois, Stati Uniti, 60429
- Reclutamento
- Advocate South Suburban Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-799-9995
-
Investigatore principale:
- Thomas J. Saphner
-
Highland Park, Illinois, Stati Uniti, 60035
- Reclutamento
- NorthShore University HealthSystem-Highland Park Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Investigatore principale:
- Robert M. Eisner
-
Hines, Illinois, Stati Uniti, 60141
- Reclutamento
- Edward Hines Jr VA Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-202-8387
-
Investigatore principale:
- Jorgena Kosti-Schwartz
-
Kewanee, Illinois, Stati Uniti, 61443
- Reclutamento
- Illinois CancerCare-Kewanee Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Lake Forest, Illinois, Stati Uniti, 60045
- Reclutamento
- Northwestern Medicine Lake Forest Hospital
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Email: cancertrials@northwestern.edu
-
Libertyville, Illinois, Stati Uniti, 60048
- Reclutamento
- AMG Libertyville - Oncology
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-929-6129
- Email: advocateresearch@advocatehealth.com
-
Investigatore principale:
- Thomas J. Saphner
-
Libertyville, Illinois, Stati Uniti, 60048
- Reclutamento
- Condell Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-929-6129
- Email: advocateresearch@advocatehealth.com
-
Investigatore principale:
- Thomas J. Saphner
-
Macomb, Illinois, Stati Uniti, 61455
- Reclutamento
- Illinois CancerCare-Macomb
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Mattoon, Illinois, Stati Uniti, 61938
- Reclutamento
- Carle Physician Group-Mattoon/Charleston
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Maywood, Illinois, Stati Uniti, 60153
- Reclutamento
- Loyola University Medical Center
-
Investigatore principale:
- Stephanie B. Tsai
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-226-4357
-
O'Fallon, Illinois, Stati Uniti, 62269
- Reclutamento
- Cancer Care Center of O'Fallon
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Stati Uniti, 60453-2699
- Reclutamento
- Advocate Christ Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-323-8622
-
Investigatore principale:
- Thomas J. Saphner
-
Oak Lawn, Illinois, Stati Uniti, 60453
- Reclutamento
- Advocate Outpatient Center - Oak Lawn
-
Investigatore principale:
- Thomas J. Saphner
-
Contatto:
- Site Public Contact
- Email: ncorp@aah.org
-
Orland Park, Illinois, Stati Uniti, 60462
- Reclutamento
- Northwestern Medicine Orland Park
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Email: nctnprogram_rhlccc@northwestern.edu
-
Ottawa, Illinois, Stati Uniti, 61350
- Reclutamento
- Illinois CancerCare-Ottawa Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Palos Heights, Illinois, Stati Uniti, 60463
- Reclutamento
- Advocate High Tech Medical Park
-
Investigatore principale:
- Thomas J. Saphner
-
Contatto:
- Site Public Contact
- Email: ncorp@aah.org
-
Park Ridge, Illinois, Stati Uniti, 60068
- Reclutamento
- Advocate Lutheran General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-384-3621
-
Investigatore principale:
- Thomas J. Saphner
-
Pekin, Illinois, Stati Uniti, 61554
- Reclutamento
- Illinois CancerCare-Pekin
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peoria, Illinois, Stati Uniti, 61615
- Reclutamento
- Illinois CancerCare-Peoria
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peoria, Illinois, Stati Uniti, 61636
- Reclutamento
- Methodist Medical Center of Illinois
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peoria, Illinois, Stati Uniti, 61637
- Reclutamento
- OSF Saint Francis Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peru, Illinois, Stati Uniti, 61354
- Reclutamento
- Illinois CancerCare-Peru
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Princeton, Illinois, Stati Uniti, 61356
- Reclutamento
- Illinois CancerCare-Princeton
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-545-7929
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Springfield Clinic
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-444-7541
-
Springfield, Illinois, Stati Uniti, 62781
- Reclutamento
- Springfield Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-528-7541
- Email: pallante.beth@mhsil.com
-
Urbana, Illinois, Stati Uniti, 61801
- Reclutamento
- Carle Cancer Center
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Warrenville, Illinois, Stati Uniti, 60555
- Reclutamento
- Northwestern Medicine Cancer Center Warrenville
-
Investigatore principale:
- Jessica K. Altman
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Washington, Illinois, Stati Uniti, 61571
- Reclutamento
- Illinois CancerCare - Washington
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Indiana University/Melvin and Bren Simon Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 317-278-5632
- Email: iutrials@iu.edu
-
Investigatore principale:
- Rita Assi
-
-
Iowa
-
Ankeny, Iowa, Stati Uniti, 50023
- Reclutamento
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Clive, Iowa, Stati Uniti, 50325
- Reclutamento
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50314
- Reclutamento
- Mercy Medical Center - Des Moines
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Richard L. Deming
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Iowa Methodist Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-6727
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50314
- Reclutamento
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-237-1225
-
Investigatore principale:
- Prajwal Dhakal
-
Pella, Iowa, Stati Uniti, 50219
- Reclutamento
- UI Healthcare Mission Cancer and Blood - Pella
-
Investigatore principale:
- Seema Harichand-Herdt
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-282-2921
- Email: trials@missioncancer.com
-
Waukee, Iowa, Stati Uniti, 50263
- Reclutamento
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
West Des Moines, Iowa, Stati Uniti, 50266
- Reclutamento
- The Iowa Clinic PC
-
Investigatore principale:
- Seema Harichand-Herdt
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-875-9815
-
-
Kansas
-
Fairway, Kansas, Stati Uniti, 66205
- Reclutamento
- University of Kansas Clinical Research Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Hays, Kansas, Stati Uniti, 67601
- Reclutamento
- HaysMed
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-623-5774
-
Investigatore principale:
- Tara L. Lin
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Lawrence, Kansas, Stati Uniti, 66044
- Reclutamento
- Lawrence Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-505-2800
- Email: Stephanie.Norris@LMH.ORG
-
Investigatore principale:
- Tara L. Lin
-
Olathe, Kansas, Stati Uniti, 66061
- Reclutamento
- The University of Kansas Cancer Center - Olathe
-
Investigatore principale:
- Tara L. Lin
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-1569
- Email: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Stati Uniti, 66211
- Reclutamento
- University of Kansas Hospital-Indian Creek Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Overland Park, Kansas, Stati Uniti, 66210
- Reclutamento
- University of Kansas Cancer Center-Overland Park
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Salina, Kansas, Stati Uniti, 67401
- Reclutamento
- Salina Regional Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-452-7038
- Email: mleepers@srhc.com
-
Investigatore principale:
- Tara L. Lin
-
Topeka, Kansas, Stati Uniti, 66606
- Reclutamento
- University of Kansas Health System Saint Francis Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-295-8000
-
Investigatore principale:
- Tara L. Lin
-
Topeka, Kansas, Stati Uniti, 66606
- Sospeso
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
Westwood, Kansas, Stati Uniti, 66205
- Reclutamento
- University of Kansas Hospital-Westwood Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- Ayman Qasrawi
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- The James Graham Brown Cancer Center at University of Louisville
-
Investigatore principale:
- Mohamed M. Hegazi
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-562-3429
-
Louisville, Kentucky, Stati Uniti, 40245
- Reclutamento
- UofL Health Medical Center Northeast
-
Investigatore principale:
- Mohamed M. Hegazi
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-852-2755
- Email: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70805
- Reclutamento
- LSU Health Baton Rouge-North Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 225-765-7659
- Email: research@ololrmc.com
-
Investigatore principale:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Reclutamento
- Our Lady of The Lake
-
Contatto:
- Site Public Contact
- Numero di telefono: 225-765-7659
-
Investigatore principale:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Reclutamento
- Our Lady of the Lake Physician Group
-
Contatto:
- Site Public Contact
- Numero di telefono: 225-765-7659
- Email: research@ololrmc.com
-
Investigatore principale:
- Harry G. Sequeira Gross
-
-
Maine
-
Brunswick, Maine, Stati Uniti, 04011
- Reclutamento
- Mid Coast Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-823-5923
- Email: ctsucontact@westat.com
-
Investigatore principale:
- Pamela Egan
-
Brunswick, Maine, Stati Uniti, 04011
- Reclutamento
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Investigatore principale:
- Pamela Egan
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Portland, Maine, Stati Uniti, 04102
- Reclutamento
- MaineHealth Maine Medical Center - Portland
-
Investigatore principale:
- Pamela Egan
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- MaineHealth Maine Medical Center- Scarborough
-
Investigatore principale:
- Pamela Egan
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
South Portland, Maine, Stati Uniti, 04106
- Reclutamento
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Investigatore principale:
- Pamela Egan
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Investigatore principale:
- Alexander J. Ambinder
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Sospeso
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-442-3324
-
Investigatore principale:
- Richard M. Stone
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Beth Israel Deaconess Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 617-667-9925
-
Investigatore principale:
- Malgorzata McMasters
-
Boston, Massachusetts, Stati Uniti, 02111
- Reclutamento
- Tufts Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 617-636-5000
- Email: ContactUsCancerCenter@TuftsMedicalCenter.org
-
Investigatore principale:
- Andreas K. Klein
-
Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- UMass Memorial Medical Center - University Campus
-
Investigatore principale:
- Jan Cerny
-
Contatto:
- Site Public Contact
- Numero di telefono: 508-856-3216
- Email: cancer.research@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Reclutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Brighton, Michigan, Stati Uniti, 48114
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Canton, Michigan, Stati Uniti, 48188
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Chelsea, Michigan, Stati Uniti, 48118
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Clinton Township, Michigan, Stati Uniti, 48038
- Reclutamento
- Henry Ford Macomb Hospital-Clinton Township
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Investigatore principale:
- Ahmad H. Mattour
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Wayne State University/Karmanos Cancer Institute
-
Investigatore principale:
- Vijendra Singh
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-527-6266
- Email: ctoadmin@karmanos.org
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Investigatore principale:
- Ahmad H. Mattour
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Reclutamento
- Weisberg Cancer Treatment Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Investigatore principale:
- Vijendra Singh
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Genesys Hurley Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Hurley Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Flint, Michigan, Stati Uniti, 48503
- Sospeso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Cancer Hematology Centers - Flint
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Jackson, Michigan, Stati Uniti, 49201
- Reclutamento
- Allegiance Health
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Investigatore principale:
- Ahmad H. Mattour
-
Livonia, Michigan, Stati Uniti, 48154
- Reclutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Novi, Michigan, Stati Uniti, 48377
- Reclutamento
- Henry Ford Medical Center-Columbus
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Investigatore principale:
- Ahmad H. Mattour
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
West Bloomfield, Michigan, Stati Uniti, 48322
- Reclutamento
- Henry Ford West Bloomfield Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Investigatore principale:
- Ahmad H. Mattour
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Tareq Al baghdadi
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Reclutamento
- Sanford Joe Lueken Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-333-5000
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Reclutamento
- Mercy Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Deer River, Minnesota, Stati Uniti, 56636
- Reclutamento
- Essentia Health - Deer River Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Duluth, Minnesota, Stati Uniti, 55805
- Reclutamento
- Essentia Health Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Fairview Southdale Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Minnesota Oncology - Edina
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Hibbing, Minnesota, Stati Uniti, 55746
- Reclutamento
- Essentia Health Hibbing Clinic
-
Investigatore principale:
- Bret E. Friday
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Reclutamento
- Abbott-Northwestern Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic in Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- James M. Foran
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Reclutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- Regions Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Saint Paul, Minnesota, Stati Uniti, 55102
- Reclutamento
- United Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Virginia, Minnesota, Stati Uniti, 55792
- Reclutamento
- Essentia Health Virginia Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
-
Mississippi
-
Columbus, Mississippi, Stati Uniti, 39705
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
Grenada, Mississippi, Stati Uniti, 38901
- Reclutamento
- Baptist Cancer Center-Grenada
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
New Albany, Mississippi, Stati Uniti, 38652
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Union County
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
Oxford, Mississippi, Stati Uniti, 38655
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
Southhaven, Mississippi, Stati Uniti, 38671
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Desoto
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
-
Missouri
-
City of Saint Peters, Missouri, Stati Uniti, 63376
- Reclutamento
- Siteman Cancer Center at Saint Peters Hospital
-
Investigatore principale:
- Geoffrey L. Uy
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Creve Coeur, Missouri, Stati Uniti, 63141
- Reclutamento
- Siteman Cancer Center at West County Hospital
-
Investigatore principale:
- Geoffrey L. Uy
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Farmington, Missouri, Stati Uniti, 63640
- Reclutamento
- Parkland Health Center - Farmington
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
Kansas City, Missouri, Stati Uniti, 64154
- Reclutamento
- University of Kansas Cancer Center - North
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- University Health Truman Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-404-4375
-
Investigatore principale:
- Tara L. Lin
-
Kansas City, Missouri, Stati Uniti, 64116
- Reclutamento
- University of Kansas Cancer Center - Briarcliff
-
Investigatore principale:
- Tara L. Lin
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
-
Lee's Summit, Missouri, Stati Uniti, 64064
- Reclutamento
- University of Kansas Cancer Center - Lee's Summit
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Investigatore principale:
- Tara L. Lin
-
Saint Joseph, Missouri, Stati Uniti, 64506
- Sospeso
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Stati Uniti, 63670
- Reclutamento
- Sainte Genevieve County Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Investigatore principale:
- Geoffrey L. Uy
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
St Louis, Missouri, Stati Uniti, 63129
- Reclutamento
- Siteman Cancer Center-South County
-
Investigatore principale:
- Geoffrey L. Uy
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
St Louis, Missouri, Stati Uniti, 63136
- Reclutamento
- Siteman Cancer Center at Christian Hospital
-
Investigatore principale:
- Geoffrey L. Uy
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
St Louis, Missouri, Stati Uniti, 63131
- Reclutamento
- Missouri Baptist Medical Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
St Louis, Missouri, Stati Uniti, 63128
- Sospeso
- Mercy Hospital South
-
Sullivan, Missouri, Stati Uniti, 63080
- Reclutamento
- Missouri Baptist Sullivan Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Reclutamento
- Community Hospital of Anaconda
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Billings, Montana, Stati Uniti, 59101
- Reclutamento
- Billings Clinic Cancer Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-996-2663
- Email: research@billingsclinic.org
-
Bozeman, Montana, Stati Uniti, 59715
- Reclutamento
- Bozeman Health Deaconess Hospital
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Great Falls, Montana, Stati Uniti, 59405
- Reclutamento
- Benefis Sletten Cancer Institute
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Kalispell, Montana, Stati Uniti, 59901
- Reclutamento
- Logan Health Medical Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Missoula, Montana, Stati Uniti, 59802
- Reclutamento
- Saint Patrick Hospital - Community Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-327-3118
- Email: amy.hanneman@providence.org
-
Investigatore principale:
- Charles W. Drescher
-
Missoula, Montana, Stati Uniti, 59804
- Reclutamento
- Community Medical Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Stati Uniti, 68123
- Reclutamento
- Nebraska Medicine-Bellevue
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Investigatore principale:
- Michael Haddadin
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Investigatore principale:
- Michael Haddadin
-
Omaha, Nebraska, Stati Uniti, 68118
- Reclutamento
- Nebraska Medicine-Village Pointe
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-5600
-
Investigatore principale:
- Michael Haddadin
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89102
- Sospeso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stati Uniti, 89183
- Sospeso
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Stati Uniti, 89502
- Sospeso
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Reclutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
Investigatore principale:
- Raphael A. Lizcano
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Reclutamento
- Memorial Sloan Kettering Basking Ridge
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
Camden, New Jersey, Stati Uniti, 08103
- Reclutamento
- Cooper Hospital University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 856-325-6757
-
Investigatore principale:
- Michael Brister
-
Livingston, New Jersey, Stati Uniti, 07039
- Reclutamento
- Cooperman Barnabas Medical Center
-
Investigatore principale:
- Neil D. Palmisiano
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-322-5200
-
Long Branch, New Jersey, Stati Uniti, 07740
- Reclutamento
- Monmouth Medical Center
-
Investigatore principale:
- Neil D. Palmisiano
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-923-6564
- Email: mary.danish@rwjbh.org
-
Middletown, New Jersey, Stati Uniti, 07748
- Reclutamento
- Memorial Sloan Kettering Monmouth
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
Montvale, New Jersey, Stati Uniti, 07645
- Reclutamento
- Memorial Sloan Kettering Bergen
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
Investigatore principale:
- Neil D. Palmisiano
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-7356
-
Paramus, New Jersey, Stati Uniti, 07652
- Reclutamento
- The Valley Hospital - Luckow Pavilion
-
Investigatore principale:
- Jason Suh
-
Contatto:
- Site Public Contact
- Numero di telefono: 201-634-5792
- Email: clinicaltrialsresearch@valleyhealth.com
-
Ridgewood, New Jersey, Stati Uniti, 07450
- Reclutamento
- Valley Health System Ridgewood Campus
-
Investigatore principale:
- Jason Suh
-
Contatto:
- Site Public Contact
- Numero di telefono: 201-634-5792
- Email: clinicaltrialsresearch@valleyhealth.com
-
Toms River, New Jersey, Stati Uniti, 08755
- Reclutamento
- Community Medical Center
-
Investigatore principale:
- Neil D. Palmisiano
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-557-8294
- Email: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Reclutamento
- University of New Mexico Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 505-925-0348
- Email: HSC-ClinicalTrialInfo@salud.unm.edu
-
Investigatore principale:
- Charles Foucar
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Reclutamento
- Roswell Park Cancer Institute
-
Investigatore principale:
- Eunice S. Wang
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-767-9355
- Email: askroswell@roswellpark.org
-
Commack, New York, Stati Uniti, 11725
- Reclutamento
- Memorial Sloan Kettering Commack
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
Lake Success, New York, Stati Uniti, 11042
- Reclutamento
- Northwell Health/Center for Advanced Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 516-734-8896
-
Investigatore principale:
- David Chitty
-
Manhasset, New York, Stati Uniti, 11030
- Reclutamento
- North Shore University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 516-734-8896
-
Investigatore principale:
- David Chitty
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Mount Sinai Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-824-7309
- Email: CCTO@mssm.edu
-
Investigatore principale:
- Douglas A. Tremblay
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 585-275-5830
-
Investigatore principale:
- Jane L. Liesveld
-
Rochester, New York, Stati Uniti, 14621
- Reclutamento
- Rochester General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 585-922-3536
- Email: tia.derosa@rochestergeneral.org
-
Investigatore principale:
- Maria M. Sbenghe
-
Stony Brook, New York, Stati Uniti, 11794
- Reclutamento
- Stony Brook University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-862-2215
-
Investigatore principale:
- Suhu Liu
-
Syracuse, New York, Stati Uniti, 13210
- Reclutamento
- State University of New York Upstate Medical University
-
Investigatore principale:
- Teresa C. Gentile
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-464-5476
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center - Moses Campus
-
Investigatore principale:
- Ioannis Mantzaris
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-379-6866
- Email: eskwak@montefiore.org
-
Uniondale, New York, Stati Uniti, 11553
- Reclutamento
- Memorial Sloan Kettering Nassau
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Aaron D. Goldberg
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Investigatore principale:
- Lacey S. Williams
-
Charlotte, North Carolina, Stati Uniti, 28203
- Reclutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-9376
-
Investigatore principale:
- Brittany K. Ragon
-
Charlotte, North Carolina, Stati Uniti, 28204
- Reclutamento
- Novant Health Presbyterian Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 980-201-6360
- Email: kashah@novanthealth.org
-
Investigatore principale:
- Patricia L. Kropf
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Harry P. Erba
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- East Carolina University
-
Investigatore principale:
- Darla K. Liles
-
Contatto:
- Site Public Contact
- Numero di telefono: 252-744-1015
- Email: eubankss@ecu.edu
-
Wilmington, North Carolina, Stati Uniti, 28401
- Reclutamento
- Novant Health New Hanover Regional Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 910-342-3000
-
Investigatore principale:
- Swaleh A. Bahamadi
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest University Health Sciences
-
Investigatore principale:
- Matthew J. Wieduwilt
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-713-6771
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Reclutamento
- Novant Health Forsyth Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-718-8335
- Email: pjordan@novanthealth.org
-
Investigatore principale:
- James P. Dugan
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Reclutamento
- Sanford Bismarck Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Roger Maris Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-234-6161
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Case Western Reserve University
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Investigatore principale:
- Benjamin K. Tomlinson
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- Ohio State University Comprehensive Cancer Center
-
Investigatore principale:
- Alice S. Mims
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-293-5066
- Email: Jamesline@osumc.edu
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Manu Pandey
-
-
Oregon
-
Newberg, Oregon, Stati Uniti, 97132
- Reclutamento
- Providence Newberg Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Investigatore principale:
- Charles W. Drescher
-
Ontario, Oregon, Stati Uniti, 97914
- Reclutamento
- Saint Alphonsus Cancer Care Center-Ontario
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Oregon City, Oregon, Stati Uniti, 97045
- Reclutamento
- Providence Willamette Falls Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Investigatore principale:
- Charles W. Drescher
-
Portland, Oregon, Stati Uniti, 97213
- Reclutamento
- Providence Portland Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Investigatore principale:
- Charles W. Drescher
-
Portland, Oregon, Stati Uniti, 97225
- Reclutamento
- Providence Saint Vincent Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Investigatore principale:
- Charles W. Drescher
-
Portland, Oregon, Stati Uniti, 97239
- Sospeso
- Oregon Health and Science University
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Investigatore principale:
- Tareq Al baghdadi
-
Danville, Pennsylvania, Stati Uniti, 17822
- Reclutamento
- Geisinger Medical Center
-
Investigatore principale:
- Joseph J. Vadakara
-
Contatto:
- Site Public Contact
- Numero di telefono: 570-271-5251
- Email: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Stati Uniti, 17033-0850
- Reclutamento
- Penn State Milton S Hershey Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-531-3779
- Email: CTO@hmc.psu.edu
-
Investigatore principale:
- Joseph Cioccio
-
Lewistown, Pennsylvania, Stati Uniti, 17044
- Reclutamento
- Lewistown Hospital
-
Investigatore principale:
- Joseph J. Vadakara
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-242-7703
- Email: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-600-9151
- Email: ONCTrialNow@jefferson.edu
-
Investigatore principale:
- Margaret T. Kasner
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania/Abramson Cancer Center
-
Investigatore principale:
- Keith W. Pratz
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-349-8245
- Email: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-647-8073
-
Investigatore principale:
- Annie P. Im
-
West Reading, Pennsylvania, Stati Uniti, 19611
- Reclutamento
- Reading Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-988-9323
-
Investigatore principale:
- Terrence P. Cescon
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
- Reclutamento
- Geisinger Wyoming Valley/Henry Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 570-271-5251
- Email: HemonCCTrials@geisinger.edu
-
Investigatore principale:
- Joseph J. Vadakara
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Rhode Island Hospital
-
Investigatore principale:
- John L. Reagan
-
Contatto:
- Site Public Contact
- Numero di telefono: 401-444-1488
-
-
South Carolina
-
Boiling Springs, South Carolina, Stati Uniti, 29316
- Reclutamento
- Prisma Health Cancer Institute - Spartanburg
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Investigatore principale:
- Praneeth Baratam
-
Contatto:
- Site Public Contact
- Numero di telefono: 843-792-9321
- Email: hcc-clinical-trials@musc.edu
-
Easley, South Carolina, Stati Uniti, 29640
- Reclutamento
- Prisma Health Cancer Institute - Easley
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health Cancer Institute - Faris
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health Cancer Institute - Butternut
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29615
- Reclutamento
- Prisma Health Cancer Institute - Eastside
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Stati Uniti, 29650
- Reclutamento
- Prisma Health Cancer Institute - Greer
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Stati Uniti, 29672
- Reclutamento
- Prisma Health Cancer Institute - Seneca
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Reclutamento
- Sanford Cancer Center Oncology Clinic
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Tennessee
-
Collierville, Tennessee, Stati Uniti, 38017
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
Knoxville, Tennessee, Stati Uniti, 37920
- Sospeso
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Stati Uniti, 38120
- Reclutamento
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Investigatore principale:
- Salil Goorha
-
Contatto:
- Site Public Contact
- Numero di telefono: 901-226-1366
- Email: BCCclintrials@bmhcc.org
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-798-1354
- Email: burton@bcm.edu
-
Investigatore principale:
- Tareq Abuasab
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Ben Taub General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-873-2000
-
Investigatore principale:
- Tareq Abuasab
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- Huntsman Cancer Institute/University of Utah
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-424-2100
- Email: cancerinfo@hci.utah.edu
-
Investigatore principale:
- Paul J. Shami
-
Salt Lake City, Utah, Stati Uniti, 84148
- Reclutamento
- George E Wahlen Department of Veterans Affairs Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 801-582-1565
-
Investigatore principale:
- Tsewang Tashi
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- Reclutamento
- University of Vermont Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 802-656-4101
- Email: rpo@uvm.edu
-
Investigatore principale:
- Diego A. Adrianzen Herrera
-
Burlington, Vermont, Stati Uniti, 05405
- Reclutamento
- University of Vermont and State Agricultural College
-
Contatto:
- Site Public Contact
- Numero di telefono: 802-656-8990
- Email: rpo@uvm.edu
-
Investigatore principale:
- Diego A. Adrianzen Herrera
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- Reclutamento
- University of Virginia Cancer Center
-
Investigatore principale:
- Daniel R. Reed
-
Contatto:
- Site Public Contact
- Numero di telefono: 434-243-6303
- Email: uvacancertrials@hscmail.mcc.virginia.edu
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Inova Schar Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 703-720-5210
- Email: Stephanie.VanBebber@inova.org
-
Investigatore principale:
- Danielle A. Shafer
-
Falls Church, Virginia, Stati Uniti, 22042
- Reclutamento
- Inova Fairfax Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 703-208-6650
- Email: Stephanie.VanBebber@inova.org
-
Investigatore principale:
- Danielle A. Shafer
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- VCU Massey Comprehensive Cancer Center
-
Investigatore principale:
- Keri R. Maher
-
Contatto:
- Site Public Contact
- Numero di telefono: 804-628-6430
- Email: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Stati Uniti, 98026
- Reclutamento
- Swedish Cancer Institute-Edmonds
-
Investigatore principale:
- Charles W. Drescher
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Stati Uniti, 98029
- Reclutamento
- Swedish Cancer Institute-Issaquah
-
Investigatore principale:
- Charles W. Drescher
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Stati Uniti, 98122
- Reclutamento
- Swedish Medical Center-First Hill
-
Investigatore principale:
- Charles W. Drescher
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington Medical Center - Montlake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-8824
-
Investigatore principale:
- Jacob S. Appelbaum
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-8824
-
Investigatore principale:
- Jacob S. Appelbaum
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- ThedaCare Regional Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3604
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Yazhini Vallatharasu
-
Ashland, Wisconsin, Stati Uniti, 54806
- Reclutamento
- Duluth Clinic Ashland
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Burlington, Wisconsin, Stati Uniti, 53105
- Reclutamento
- Aurora Cancer Care-Southern Lakes VLCC
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Cudahy, Wisconsin, Stati Uniti, 53110
- Reclutamento
- Aurora Saint Luke's South Shore
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Reclutamento
- Marshfield Medical Center-EC Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
Germantown, Wisconsin, Stati Uniti, 53022
- Reclutamento
- Aurora Health Care Germantown Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Grafton, Wisconsin, Stati Uniti, 53024
- Reclutamento
- Aurora Cancer Care-Grafton
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Reclutamento
- Aurora BayCare Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Reclutamento
- Saint Vincent Hospital Cancer Center Green Bay
-
Investigatore principale:
- Matthew L. Ryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, Stati Uniti, 54303
- Reclutamento
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Investigatore principale:
- Matthew L. Ryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: wi_research_admin@hshs.org
-
Janesville, Wisconsin, Stati Uniti, 53548
- Reclutamento
- Mercyhealth Hospital and Cancer Center - Janesville
-
Contatto:
- Site Public Contact
- Numero di telefono: 608-756-6871
- Email: oncologyclinicaltrials@mhemail.org
-
Investigatore principale:
- Emily G. Robinson
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Reclutamento
- Aurora Cancer Care-Kenosha South
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Reclutamento
- Gundersen Lutheran Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 608-775-2385
- Email: cancerctr@gundersenhealth.org
-
Investigatore principale:
- David E. Marinier
-
Madison, Wisconsin, Stati Uniti, 53705
- Reclutamento
- William S Middleton VA Medical Center
-
Investigatore principale:
- Christopher D. Fletcher
-
Contatto:
- Site Public Contact
- Numero di telefono: 17007 608-256-1901
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Investigatore principale:
- Kieran D. Sahasrabudhe
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Stati Uniti, 53718
- Reclutamento
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Investigatore principale:
- Kieran D. Sahasrabudhe
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, Stati Uniti, 54143
- Reclutamento
- Aurora Bay Area Medical Group-Marinette
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Reclutamento
- Marshfield Medical Center-Marshfield
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
Menomonee Falls, Wisconsin, Stati Uniti, 53051
- Reclutamento
- Froedtert Menomonee Falls Hospital
-
Investigatore principale:
- Ehab L. Atallah
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-257-5100
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Reclutamento
- Aurora Cancer Care-Milwaukee
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Reclutamento
- Aurora Saint Luke's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Medical College of Wisconsin
-
Investigatore principale:
- Ehab L. Atallah
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-3666
-
Milwaukee, Wisconsin, Stati Uniti, 53233
- Reclutamento
- Aurora Sinai Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Reclutamento
- Marshfield Medical Center - Minocqua
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- Reclutamento
- ProHealth D N Greenwald Center
-
Contatto:
- Site Public Contact
- Email: research.institute@phci.org
-
Investigatore principale:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, Stati Uniti, 53151
- Reclutamento
- Froedtert and MCW Moorland Reserve Health Center
-
Investigatore principale:
- Ehab L. Atallah
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-0505
-
Oak Creek, Wisconsin, Stati Uniti, 53154
- Reclutamento
- Drexel Town Square Health Center
-
Investigatore principale:
- Ehab L. Atallah
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-0505
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- Reclutamento
- ProHealth Oconomowoc Memorial Hospital
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-7878
-
Oconto Falls, Wisconsin, Stati Uniti, 54154
- Reclutamento
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Investigatore principale:
- Matthew L. Ryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Reclutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Racine, Wisconsin, Stati Uniti, 53406
- Reclutamento
- Aurora Cancer Care-Racine
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Reclutamento
- Marshfield Medical Center-Rice Lake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Reclutamento
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Reclutamento
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Investigatore principale:
- Matthew L. Ryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: wi_research_admin@hshs.org
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Reclutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
Sturgeon Bay, Wisconsin, Stati Uniti, 54235-1495
- Reclutamento
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Investigatore principale:
- Matthew L. Ryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: wi_research_admin@hshs.org
-
Summit, Wisconsin, Stati Uniti, 53066
- Reclutamento
- Aurora Medical Center in Summit
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Reclutamento
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- ProHealth Waukesha Memorial Hospital
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-7632
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- UW Cancer Center at ProHealth Care
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-5539
- Email: Chanda.miller@phci.org
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Aurora Cancer Care-Milwaukee West
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
West Allis, Wisconsin, Stati Uniti, 53227
- Reclutamento
- Aurora West Allis Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
West Bend, Wisconsin, Stati Uniti, 53095
- Reclutamento
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Investigatore principale:
- Ehab L. Atallah
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-0505
-
Weston, Wisconsin, Stati Uniti, 54476
- Reclutamento
- Marshfield Medical Center - Weston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Adedayo A. Onitilo
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.
-
Participants must be >= 18 years of age.
-
Participants must not have received prior anti-cancer therapy for AML or MDS.
- Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction.
-
Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.
- Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
-
Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy
- Note: active hormonal therapy is allowed
-
Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.
-
Participants must agree to have translational medicine specimens submitted.
-
Participants must be offered the opportunity to participate in specimen banking.
- Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Selezione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: MM1MDS-A01 Regimen 1 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)
Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM1MDS-CTG02 Arm 1 (Luspatercept)
Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given SC
Altri nomi:
|
|
Sperimentale: MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)
Patients receive luspatercept SC on day 1 and epoetin alfa SC QW for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Given SC
Altri nomi:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given SC
Altri nomi:
|
|
Sperimentale: MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)
Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given SC
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Comparatore attivo: MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Comparatore attivo: MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1OA-MDS-A05 Cohort C (olutasidenib)
Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Comparatore attivo: MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Comparatore attivo: MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Comparatore attivo: MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)
Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Receive SOC treatment
Altri nomi:
|
|
Sperimentale: MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)
Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Receive SOC treatment
Altri nomi:
|
|
Sperimentale: MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Comparatore attivo: MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)
See Detailed Description. |
Given IV
Altri nomi:
Undergo bone marrow biopsy
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)
See Detailed Description. |
Undergo bone marrow biopsy
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given PO
Altri nomi:
|
|
Comparatore attivo: MM1YA-S01 Arm I (cytarabine, daunorubicin)
Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-S01 Arm III (azacitidine, venetoclax)
Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given IV or SC
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-S01 Arm IV (Vyxeos)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: MM1YA-S01 Arm V (Vyxeos, venetoclax)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given PO
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Comparatore attivo: MM2YA-EA01 Arm A (cytarabine)
Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo biopsy
Altri nomi:
|
|
Sperimentale: MM2YA-EA01 Arm B (cytarabine, venetoclax)
Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
|
|
Sperimentale: MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: MM2YA-EA01 Arm D (azacitidine, venetoclax)
Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo biopsy
Altri nomi:
Given PO
Altri nomi:
Given IV or SC
Altri nomi:
|
|
Sperimentale: MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given IV
Altri nomi:
Undergo chest x-ray
Altri nomi:
Given IV
Altri nomi:
|
|
Comparatore placebo: MM3TCT-A03 Conditioning 1B (matched donors with placebo)
Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given IV
Altri nomi:
Undergo chest x-ray
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo PET
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given IV
Altri nomi:
Undergo chest x-ray
Altri nomi:
Given IV
Altri nomi:
Undergo total body irradiation
Altri nomi:
|
|
Comparatore placebo: MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)
Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
Given IV
Altri nomi:
Undergo chest x-ray
Altri nomi:
Given IV
Altri nomi:
Undergo total body irradiation
Altri nomi:
|
|
Sperimentale: MM3TCT-A03 Maintenance I (venetoclax)
Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo PET
Altri nomi:
Given PO
Altri nomi:
Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Comparatore placebo: MM3TCT-A03 Maintenance II (placebo)
Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Undergo CT
Altri nomi:
Undergo PET
Altri nomi:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Altri nomi:
|
|
Sperimentale: Screening (mutation carrier screening)
Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP. |
Undergo rapid genetic testing |
|
Sperimentale: TAP (SOC treatment, mutation carrier screening)
Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment. |
Receive SOC treatment
Altri nomi:
Undergo rapid genetic testing |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a myeloMATCH clinical trial or determination that no assignment is available, within 72 hours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent therapy. For first treatment assignment and separately for each subsequent treatment assignments: every 50 participants for the first 250 participants and then every 100 participants thereafter, the proportion of participants (cumulative and new participants since prior analysis) with all MDNet data needed to determine a treatment assignment within 72 hours for first assignment and 10 days for subsequent assignments after the MDNet receives specimens will be tallied. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to MDNet generating all data required for treatment substudy or TAP assignment
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time to treatment substudy or TAP assignment
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent assigned to a myeloMATCH clinical trial
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent of screened participants who register to a treatment substudy
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Assignment to higher tier treatment substudies within myeloMATCH
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Adverse events
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Minimal residual disease (MRD) response
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
MRD response is based on flow cytometry studies performed by the MDnet. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time-to-event outcomes for exploratory analysis
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Performance status
Lasso di tempo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Participants will be graded according to the Zubrod performance status scale. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jerald P Radich, SWOG Cancer Research Network
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Malattie ematologiche
- Leucemia, mieloide
- Malattie del midollo osseo
- Leucemia
- Malattie emiche e linfatiche
- Leucemia, mieloide, acuta
- Sindromi mielodisplastiche
- Malattie mieloproliferative
- Amministrazione dei servizi sanitari
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Preparati farmaceutici
- Tecniche investigative
- Terapie
- Forme di dosaggio
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Rotte della somministrazione di droga
- Terapia farmacologica
- Tecniche citologiche
- Acidi nucleici, nucleotidi e nucleosidi
- Citodiagnosi
- Idrocarburi, aciclici
- Idrocarburi
- Idrocarburi, ciclici
- Fattori biologici
- Qualità dell'assistenza sanitaria
- Carboidrati
- Fenomeni fisici
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Indicatori di qualità, assistenza sanitaria
- Trapianto
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Aminoacidi
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Alcani
- Tecniche diagnostiche, chirurgiche
- Materiali biomedici e dentali
- Materiali fabbricati
- Tecnologia, industria e agricoltura
- Alcoli
- Tecniche di chimica, analitiche
- Glicoli butilene
- Glicoli
- Mesilati
- Alcanesolfonati
- Acidi alcanesolfonici
- Acidi solfonici
- Acidi zolfo
- Analisi dello spettro
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Composti aza
- Nucleosidi
- Ribonucleosidi
- Peptidi e proteine di segnalazione intercellulare
- Arabinonucleosidi
- Antracicline
- Naftaceni
- Aminoglicosidi
- Glicoproteine
- Glicoconiugati
- Fenomeni elettromagnetici
- Fenomeni magnetici
- Radioterapia
- Trapianto di cellule
- Terapia a base di cellule e tessuti
- Terapia biologica
- Fenilalanina
- Aminoacidi, aromatici
- Aminoacidi, ciclici
- Radiazioni elettromagnetiche
- Radiazione
- Radiazione, ionizzante
- Linee guida come argomento
- Assicurazione della qualità, assistenza sanitaria
- Fattori stimolanti le colonie
- Fattori di crescita delle cellule ematopoietiche
- Citochine
- Calicheamicins
- Membrane, artificiali
- Vettori di droga
- Materiali biomimetici
- Eritropoietina
- Epoetina Alfa
- Gemtuzumab
- Citarabina
- Melfalan
- Azacitidina
- Daunorubicina
- Busulfan
- Iniezioni
- Standard di cura
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- fludarabina
- Venetoclax
- Trapianto di cellule staminali
- combinazione di droga di decitabina e cedazuridina
- Raggi X.
- Pratica le linee guida come argomento
- Irradiazione per tutto il corpo
- enasidenib
- Quizartinib
- Gilteritinib
- CPX-351
- Liposomi
- CA-4948
- olutasidenib
- Luspatercept
Altri numeri di identificazione dello studio
- NCI-2022-07006
- U10CA180888 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2022-07006 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- MYELOMATCH (Altro identificatore: CTEP)
- MYELOMATCH (Altro identificatore: SWOG)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .